Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.53 |
| ▸ | RORC | P51449 | 7/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976127 | 0.90 | NR1H2 (0.42) | NR1H2NR1H3RORCNR1I2NR3C1 | |
| SCHEMBL1976150 | 0.90 | PTGER4 (0.43) | NR1H2NR1H3RORCGRM2NR1I2 | |
| SCHEMBL1551636 | 0.89 | NR1H2 (0.47) | NR1H2NR1H3RORCGRM2NR1I2 | |
| SCHEMBL1551027 | 0.89 | NR1H2 (0.47) | NR1H2NR1H3RORCGRM2NR1I2 | |
| SCHEMBL1552131 | 0.89 | CHRM1 (0.46) | NR1H2NR1H3RORCNR1I2NR3C1 | |
| SCHEMBL1551449 | 0.88 | NR1H2 (0.47) | NR1H2NR1H3RORCNR1I2NR3C1 | |
| SCHEMBL1551105 | 0.87 | NR1H2 (0.52) | NR1H2NR1H3RORCGRM2CYP1A2 | |
| SCHEMBL1976917 | 0.86 | BUB1 (0.42) | NR1H2NR1H3RORCNR1I2NR3C1 | |
| SCHEMBL1974882 | 0.85 | NR1H2 (0.44) | NR1H2NR1H3RORCNR1I2NR3C1 | |
| SCHEMBL1976393 | 0.85 | NR1H2 (0.46) | NR1H2NR1H3RORCCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313376-B1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-24 | — | — | EP | claimed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | claimed |
| JP-2011527323-A | — | — | 2011-10-27 | — | — | JP | claimed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2313376-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-04-27 | — | — | EP | claimed |
| WO-2010004215-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | claimed |
| EP-2313376-B1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CNR1, CNR2, GPR18 | NR1H2 535/4885NR1H3 458/4885RORC 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.